Eulexin: Advanced Androgen Blockade for Prostate Cancer Control
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.70 | $51.13 (0%) | 🛒 Add to cart |
| 60 | $1.57 | $102.25 $94.23 (8%) | 🛒 Add to cart |
| 90 | $1.50 | $153.38 $135.34 (12%) | 🛒 Add to cart |
| 120 | $1.46 | $204.51 $175.44 (14%) | 🛒 Add to cart |
| 180 | $1.41 | $306.76 $253.63 (17%) | 🛒 Add to cart |
| 270 | $1.38 | $460.15 $372.93 (19%) | 🛒 Add to cart |
| 360 | $1.32
Best per pill | $613.53 $476.19 (22%) | 🛒 Add to cart |
Synonyms
| |||
Eulexin (flutamide) is a nonsteroidal antiandrogen medication specifically designed for the treatment of metastatic prostate cancer. It works by blocking the effects of androgens, such as testosterone, which can fuel the growth of prostate cancer cells. When used in combination with a luteinizing hormone-releasing hormone (LHRH) agonist, Eulexin provides a comprehensive hormonal therapy approach, helping to slow disease progression, manage symptoms, and improve quality of life. This targeted mechanism makes it a cornerstone in the medical management of advanced prostate cancer, offering a well-tolerated option for many patients.
Features
- Contains flutamide as the active ingredient
- Available in 125 mg oral capsules
- Nonsteroidal antiandrogen class medication
- Designed for use in combination with an LHRH agonist
- Manufactured under strict pharmaceutical quality standards
Benefits
- Effectively blocks androgen receptors, reducing tumor stimulation
- Helps control cancer progression and metastatic spread
- Can alleviate urinary and pain symptoms associated with advanced prostate cancer
- Works synergistically with LHRH agonists for complete androgen blockade
- Generally well-tolerated with a predictable side effect profile
- Oral administration allows for convenient at-home treatment
Common use
Eulexin is primarily indicated for use in combination with an LHRH agonist (such as leuprolide or goserelin) for the treatment of metastatic prostate carcinoma (stage D2). This combination therapy approach, known as combined androgen blockade, provides more complete suppression of androgen stimulation to prostate cancer cells than either medication alone. It is typically initiated when patients have advanced disease that has spread beyond the prostate gland, helping to control cancer growth and manage associated symptoms.
Dosage and direction
The recommended adult dosage is one 125 mg capsule taken orally three times daily at approximately 8-hour intervals. Eulexin should be initiated simultaneously with an LHRH agonist, as the combination provides optimal therapeutic effect. Capsules may be taken with or without food, though consistency in administration relative to meals is recommended. Treatment typically continues until disease progression or unacceptable toxicity occurs. Dosage adjustments may be necessary in patients with hepatic impairment, and regular monitoring of liver function is essential throughout therapy.
Precautions
Regular monitoring of liver function tests is mandatory during treatment, as hepatotoxicity may occur. Patients should be advised to report any signs of liver dysfunction, including nausea, vomiting, abdominal pain, fatigue, anorexia, flu-like symptoms, dark urine, or jaundice. Blood counts should be monitored periodically due to potential hematologic effects. Patients with glucose-6-phosphate dehydrogenase deficiency should use Eulexin with caution due to risk of hemolytic anemia. Caution is advised when operating machinery or driving until the patient’s response to therapy is known.
Contraindications
Eulexin is contraindicated in patients with known hypersensitivity to flutamide or any component of the formulation. It should not be used in patients with severe hepatic impairment (Child-Pugh Class C). The medication is contraindicated in women, particularly during pregnancy, due to potential fetal harm. It must not be used in pediatric patients as safety and effectiveness have not been established in children. Patients with existing severe hematologic disorders should avoid Eulexin unless potential benefits outweigh risks.
Possible side effect
Common side effects include hot flashes (50-60% of patients), loss of libido (30-40%), diarrhea (12-25%), nausea and vomiting (10-15%), and gynecomastia (5-10%). Less frequently, patients may experience hepatic toxicity (elevated transaminases in 5-8%, clinical hepatitis in <1%), hematologic changes (anemia, leukopenia), visual disturbances, hypertension, or edema. Rare but serious adverse effects include liver failure, cholestatic jaundice, and hepatic necrosis. Most side effects are dose-dependent and may improve with dosage adjustment or symptomatic management.
Drug interaction
Eulexin may interact with warfarin and other coumarin-derived anticoagulants, potentially increasing prothrombin time and risk of bleeding. Close monitoring of INR is recommended when used concomitantly. The medication may alter metabolism of drugs processed by CYP1A2, CYP2C9, and CYP3A4 enzymes. Concomitant use with other hepatotoxic drugs may increase risk of liver injury. LHRH agonists used in combination do not typically cause significant interactions but require separate administration considerations. Physicians should review all concomitant medications, including over-the-counter products and supplements.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take double or extra doses to make up for a missed dose. Maintaining consistent dosing intervals is important for stable androgen blockade. If multiple doses are missed or vomiting occurs shortly after administration, patients should contact their healthcare provider for guidance on resuming therapy.
Overdose
Symptoms of overdose may include exaggerated pharmacological effects such as increased hot flashes, gastrointestinal distress, dizziness, or potential hepatic toxicity. There is no specific antidote for Eulexin overdose. Treatment should be symptomatic and supportive, including gastric lavage if ingestion was recent. Liver function should be monitored closely, and appropriate supportive care provided based on clinical manifestations. Patients should be advised to seek immediate medical attention if overdose is suspected. Hemodialysis is not likely to be effective due to high protein binding.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture and light. Do not store in bathroom cabinets where humidity levels may fluctuate. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly discard any unused medication that is no longer needed or has expired.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare professional who can consider individual patient factors, including complete medical history, current medications, and specific health status. Dosage and administration may vary based on individual patient needs and response to therapy. Always follow the prescribing information provided by the manufacturer and the guidance of your treating physician.
Reviews
Clinical studies have demonstrated Eulexin’s efficacy in combination therapy for metastatic prostate cancer, with many urologists and oncologists reporting positive outcomes in disease control and symptom management. Patients often note improvement in cancer-related symptoms, though many experience expected side effects such as hot flashes. The convenience of oral administration is frequently cited as beneficial compared to injectable alternatives. Healthcare providers emphasize the importance of regular monitoring and adherence to dosing schedules for optimal results. Long-term experience supports its role as a valuable component in prostate cancer management protocols.